

Supplemental Table 1. Pooled Multivariable Relative Risks (95% Confidence Intervals) of Prostate Cancer According to Measures of Body Fatness, Adjusted for BMI at Baseline

HR (95% CI) by Categories of Anthropometric Factor						p-value, test for trend ²	p-value, test for between- studies heterogeneity ³	I ² ⁴	p-value, test for common effects ⁵	Continuous HR (95% CI) ⁶	p-value, test for between- studies heterogeneity	I ²
BMI at Younger Ages (kg/m²)												
All	<18.5	18.5-20.9	21-22.9	23.24.9	≥25							
	0.97 (0.93-1.01)	0.99 (0.97-1.02)	1.00 (REF)	0.98 (0.96-1.02)	0.95 (0.91-0.99)	0.59	0.29	18%		** ¹³		
By stage												
Localized ⁷	0.96 (0.92-1.01)	1.01 (0.97-1.04)	1.00 (REF)	0.99 (0.95-1.02)	0.94 (0.90-0.99)	0.05	0.34	12%		** ¹³		
Advanced ⁸	0.87 (0.70-1.10)	0.95 (0.87-1.04)	1.00 (REF)	0.92 (0.77-1.10)	0.94 (0.81-1.09)	0.87	0.19	29%	0.65	0.98 (0.86-1.12)	<0.01	70%
Restricted ⁹	0.99 (0.78-1.25)	0.95 (0.85-1.07)	1.00 (REF)	0.89 (0.71-1.12)	0.92 (0.78-1.08)	0.77	0.37	8%	0.94	0.97 (0.85-1.11)	0.03	56%
Prostate Cancer Mortality ¹⁰	0.90 (0.65-1.24)	0.93 (0.83-1.04)	1.00 (REF)	0.95 (0.80-1.12)	0.95 (0.81-1.10)	0.74	0.42	2%	0.97	1.00 (0.85-1.17)	<0.01	69%
By grade												
Low ¹¹	0.95 (0.90-0.99)	1.00 (0.97-1.04)	1.00 (REF)	0.98 (0.94-1.02)	0.95 (0.90-1.01)	0.52	0.09	41%		** ¹³		
High ¹²	0.99 (0.90-1.08)	0.95 (0.88-1.02)	1.00 (REF)	0.98 (0.88-1.08)	0.95 (0.88-1.03)	0.79	0.46	0%	0.91	1.00 (0.95-1.04)	0.81	0%
Waist Circumference (cm)												
All	<90	90-<100	100-<110	≥110								
	1.00 (REF)	1.02 (0.97-1.07)	1.02 (0.98-1.07)	1.00 (0.94-1.07)		0.84	0.69	0%		** ¹³		
By stage												
Localized ⁷	1.00 (REF)	1.03 (0.98-1.09)	1.03 (0.97-1.08)	1.02 (0.94-1.10)		0.88	0.72	0%		** ¹³		
Advanced ⁸	1.00 (REF)	1.00 (0.87-1.14)	1.08 (0.91-1.27)	1.17 (0.93-1.47)		0.14	0.43	0%	0.26	1.03 (0.98-1.07)	0.49	0%
Restricted ⁹	1.00 (REF)	0.96 (0.80-1.14)	1.08 (0.87-1.35)	1.01 (0.73-1.38)		0.53	0.55	0%	0.95	1.01 (0.95-1.08)	0.55	0%
Prostate Cancer Mortality ¹⁰	1.00 (REF)	1.03 (0.85-1.26)	1.04 (0.81-1.33)	1.28 (0.97-1.70)		0.15	0.43	0%	0.11	1.04 (0.99-1.09)	0.64	0%
By grade												
Low ¹¹	1.00 (REF)	1.03 (0.98-1.08)	1.01 (0.95-1.07)	0.97 (0.90-1.05)		0.43	0.43	0%		** ¹³		
High ¹²	1.00 (REF)	1.06 (0.97-1.17)	1.16 (0.97-1.39)	1.21 (1.03-1.43)		0.04	0.39	6%	0.02	** ¹³		
Hip Circumference (cm)												
All	<95	95-<100	100-<105	≥105								
	1.00 (REF)	0.98 (0.92-1.05)	1.01 (0.95-1.09)	0.93 (0.87-1.00)		0.032	0.29	23%		** ¹³		
By stage												
Localized ⁷	1.00 (REF)	0.99 (0.94-1.05)	1.02 (0.96-1.08)	0.95 (0.88-1.01)		0.09	0.62	0%		** ¹³		
Advanced ⁸	1.00 (REF)	1.01 (0.81-1.26)	1.04 (0.78-1.40)	0.97 (0.75-1.25)		0.53	0.22	32%	0.86	1.00 (0.96-1.04)	0.53	0%
Restricted ⁹	1.00 (REF)	0.93 (0.69-1.24)	0.98 (0.70-1.37)	0.77 (0.52-1.14)		0.16	0.11	51%	0.32	** ¹³		
Prostate Cancer Mortality ¹⁰	1.00 (REF)	1.00 (0.79-1.26)	1.16 (0.75-1.81)	1.16 (0.84-1.60)		0.36	0.20	34%	0.22	1.03 (0.98-1.07)	0.61	0%
By grade												
Low ¹¹	1.00 (REF)	1.00 (0.95-1.06)	1.01 (0.95-1.07)	0.91 (0.83-1.00)		0.03	0.25	30%		** ¹³		
High ¹²	1.00 (REF)	0.97 (0.86-1.09)	1.12 (0.87-1.44)	1.06 (0.84-1.35)		0.72	0.13	53%	0.23	1.01 (0.98-1.04)	0.30	25%

Waist to Hip Ratio		<0.90	0.90-<0.95	0.95-<1.00	≥1.00							
All		1.00 (REF)	1.02 (0.96-1.09)	1.05 (0.98-1.12)	1.11 (1.03-1.19)	<0.01	0.67	0%	1.02 (1.00-1.03)	0.55	0%	
By stage												
	Localized ⁷	1.00 (REF)	1.03 (0.97-1.09)	1.05 (0.99-1.11)	1.06 (1.00-1.13)	0.09	0.43	0%	1.02 (1.00-1.03)	0.52	0%	
	Advanced ⁸	1.00 (REF)	1.05 (0.90-1.21)	1.03 (0.86-1.23)	1.18 (0.99-1.41)	0.09	0.42	0%	0.28	1.06 (1.01-1.11)	0.47	0%
	Restricted ⁹	1.00 (REF)	1.05 (0.77-1.43)	1.01 (0.82-1.25)	1.15 (0.88-1.51)	0.40	0.30	19%	0.58	1.04 (0.97-1.11)	0.88	0%
	Prostate Cancer Mortality ¹⁰	1.00 (REF)	1.01 (0.83-1.22)	0.98 (0.73-1.31)	1.13 (0.92-1.40)	0.27	0.61	0%	0.58	** ¹³		
By grade												
	Low ¹¹	1.00 (REF)	1.03 (0.97-1.08)	1.04 (0.99-1.10)	1.08 (0.99-1.19)	0.11	0.16	44%		1.02 (0.99-1.05)	0.10	53%
	High ¹²	1.00 (REF)	1.08 (0.94-1.24)	1.08 (0.96-1.21)	1.13 (1.00-1.28)	0.11	0.49	0%	0.60	1.04 (1.01-1.08)	0.44	0%

¹Multivariable relative risks (MVRR) were adjusted for race (Caucasian, African-American, Asian, Hispanic, other), education (<high school, high school, >high school), marital status (married, never married, widowed, divorced), alcohol (0, >0-<5, 5-<15, 15-<30 and ≥30g/day), smoking habits (never, past smoker and <15 pack years, past smoker and 15+ pack years, current smoker and <40 pack years, and current smoker and pack years ≥40), height (<1.70, 1.70-<1.75, 1.75-<1.80, 1.80-<1.85, ≥1.85m), except for JPHC1 and JPHC2 in which the .05m category increments ranged from <1.60 to >1.75m, BMI (<23, 23-<25, 25-<30, ≥30kg/m²), (physical activity (low, medium, high), prostate cancer family history (no, yes), personal history of diabetes (no, yes) multiple vitamin use (no, yes), and dietary calcium (quintiles), dietary lycopene (quintiles), and total energy intake (kcal/d, continuous); for adjustment, these

²P-value, test for trend is evaluated using the Wald test

³P-value, test for between-studies heterogeneity is based on the highest category

⁴I² value is based on the highest category

⁵P-value, contrast test, is based on the highest category and compared the following: 1)advanced to localized, 2) advanced restricted to localized, 3) prostate cancer mortality to localized, and 4) high grade to low grade.

⁶Continuous estimate was based on an increment of 10cm for waist circumference, 5cm for hip circumference and 0.05 for waist to hip ratio.

⁷"Localized": defined as cancers with information on stage but are not defined as "periprostic", i.e. cancers confined within the prostate;

⁸"Advanced": defined as cancers with extension to or fixation to adjacent structures other than seminal vesicles, i.e. T4, N1, M1 or fatal;

⁹"Advanced (restricted)": same as "advanced" but excluding localized cases and cases with missing stage, who died of prostate cancer during follow-up;

¹⁰"Prostate Cancer Mortality": defined when prostate cancer was the underlying cause of death

¹¹"Low grade": Gleason score <8 or well/moderately differentiated

¹²"High grade": Gleason score ≥8 or poorly differentiated/undifferentiated

¹³Continuous estimates were not calculated as the p-value, test for nonlinearity<0.05

Supplemental Table 2. Pooled Multivariable Hazard Ratios¹ (95% Confidence Intervals) of Prostate Cancer For Anthropometric Factors Stratified by Age, Follow-up Time, Smoking status and Physical Activity and Among Non-Diabetics

		BMI at baseline ²				BMI in early adulthood ²				Height ²				Waist Circumference ²				Waist Circumference ^{2,3}			
		p-value, test for between-studies heteroge		p-value, test for interaction ⁶		p-value, test for between-studies heteroge		p-value, test for interaction ⁶		p-value, test for between-studies heteroge		p-value, test for interaction ⁶		p-value, test for between-studies heteroge		p-value, test for interaction ⁶		p-value, test for between-studies heteroge		p-value, test for interaction ⁶	
		Cont	neity ⁴	I ² ⁵		Cont	neity ⁴	I ² ⁵		Cont	neity ⁴	I ² ⁵		Cont	neity ⁴	I ² ⁵		Cont	neity ⁴	I ² ⁵	
Stratified by Age																					
Advanced ⁷	<60 years old	1.04 (0.88-1.23)	0.26	22%	0.81	0.99 (0.67-1.45)	0.01	67%	0.55	1.06 (1.03-1.08)	0.41	4%	0.42	1.24 (0.96-1.60)	0.12	53%	0.13	1.17 (0.84-1.63)	<0.01	78%	0.29
	>=60 years old	1.06 (1.01-1.12)	0.35	10%		1.00 (0.88-1.14)	<0.01	69%		1.02 (0.93-1.13)	0.41	31%		1.02 (0.97-1.07)	0.52	0%		1.04 (0.98-1.11)	0.17	36%	
Advanced restricted ⁸	<60 years old	1.01 (0.80-1.28)	0.11	41%	0.92	0.93 (0.53-1.64)	<0.01	79%	0.19	0.98 (0.89-1.08)	0.88	0%	0.18	1.06 (0.86-1.31)	0.36	13%	0.59	1.03 (0.71-1.48)	<0.01	71%	0.90
	>=60 years old	1.02 (0.95-1.09)	0.29	17%		0.97 (0.84-1.11)	0.02	57%		1.05 (1.02-1.08)	0.73	0%		1.01 (0.93-1.08)	0.38	7%		0.99 (0.93-1.07)	0.32	16%	
Prostate Cancer Mortality ⁹	<60 years old	0.96 (0.64-1.44)	0.13	44%	0.46	0.65 (0.39-1.08)	0.83	0%	0.11	1.10 (0.92-1.30)	0.66	0%	0.90	1.71 (1.13-2.58)	0.66	0%	0.02	1.09 (0.51-2.32)	0.05	74%	0.77
	>=60 years old	1.10 (1.04-1.16)	0.45	0%		0.97 (0.84-1.11)	0.02	57%		1.07 (1.04-1.10)	0.28	19%		1.03 (0.98-1.08)	0.76	0%		1.07 (1.01-1.13)	0.28	24%	
Stratified by Follow Up Time																					
Advanced ⁷	<5 years	1.06 (0.99-1.12)	0.51	0%	0.71	1.02 (0.92-1.13)	0.28	19%	0.69	1.04 (1.01-1.07)	0.57	0%	0.41	1.04 (0.97-1.11)	0.77	0%	0.95	1.05 (0.97-1.13)	0.26	24%	
	>=5 years	1.08 (1.01-1.16)	0.22	23%		1.00 (0.85-1.18)	<0.01	68%		1.05 (1.01-1.10)	0.07	41%		1.03 (0.95-1.12)	0.46	0%		1.04 (0.97-1.11)	0.37	8%	0.75
Advanced restricted ⁸	<5 years	0.96 (0.89-1.05)	0.45	0%	0.13	0.99 (0.86-1.13)	0.34	12%	0.98	1.04 (1.00-1.09)	0.82	0%	0.52	1.05 (0.94-1.17)	0.35	16%	0.41	1.00 (0.90-1.12)	0.29	21%	
	>=5 years	1.05 (0.98-1.13)	0.57	0%		0.98 (0.82-1.18)	0.01	63%		1.05 (1.00-1.09)	0.27	20%		0.98 (0.88-1.10)	0.94	0%		1.00 (0.92-1.08)	0.95	0%	0.97
Prostate Cancer Mortality ⁹	<5 years	1.11 (1.01-1.22)	0.31	17%	0.80	1.04 (0.90-1.19)	0.22	26%	0.48	1.05 (1.01-1.09)	0.72	0%	0.18	1.03 (0.96-1.12)	0.92	0%	0.61	1.08 (0.99-1.18)	0.63	0%	
	>=5 years	1.10 (1.01-1.20)	0.36	9%		0.99 (0.84-1.17)	0.10	43%		1.08 (1.02-1.14)	0.07	45%		1.07 (0.96-1.20)	0.62	0%		1.11 (1.02-1.21)	0.36	10%	0.64
Stratified by Smoking Status																					
Advanced ⁷	Never	1.12 (0.99-1.27)	0.03	18%	0.67	1.02 (0.89-1.18)	0.18	31%	0.63	1.06 (0.99-1.13)	0.02	55%	0.09	1.07 (0.96-1.20)	0.52	0%	0.53	1.06 (0.95-1.18)	0.14	41%	0.57
	Former	1.06 (0.99-1.13)	0.42	3%		0.99 (0.87-1.12)	0.10	40%		1.02 (0.99-1.06)	0.32	15%		1.00 (0.91-1.10)	0.71	0%		1.03 (0.96-1.10)	0.40	4%	
	Current	1.06 (0.96-1.18)	0.25	23%		1.03 (0.79-1.35)	0.01	64%		1.09 (1.04-1.14)	0.74	0%		1.16 (0.96-1.38)	0.16	57%		1.12 (0.98-1.28)	0.20	35%	
Advanced restricted ⁸	Never	1.06 (0.93-1.22)	0.14	37%	0.25	1.02 (0.87-1.20)	0.32	15%	0.59	1.03 (0.98-1.09)	0.64	0%	0.23	1.02 (0.87-1.18)	0.48	0%	0.31	1.00 (0.90-1.12)	0.49	0%	0.31
	Former	0.97 (0.90-1.06)	0.94	0%		0.94 (0.80-1.10)	0.12	39%		1.02 (0.98-1.06)	0.95	0%		0.95 (0.84-1.08)	0.43	0%		0.95 (0.85-1.06)	0.22	31%	
	Current	1.08 (0.94-1.23)	0.20	31%		1.01 (0.76-1.33)	0.09	47%		1.10 (1.04-1.17)	0.47	0%		1.32 (0.99-1.77)	<0.05	82%		1.18 (0.97-1.44)	0.14	44%	
Prostate Cancer Mortality ⁹	Never	1.18 (1.01-1.38)	0.04	52%	0.69	1.03 (0.89-1.18)	0.53	0	0.60	1.08 (1.02-1.13)	0.62	0%	0.22	1.11 (0.91-1.35)	0.09	49%	0.46	1.10 (0.98-1.25)	0.22	29%	0.77
	Former	1.11 (1.03-1.21)	0.95	0%		1.02 (0.86-1.20)	0.05	49%		1.04 (1.00-1.08)	0.47	0%		1.01 (0.90-1.13)	0.65	0%		1.07 (0.99-1.16)	0.63	0%	
	Current	1.08 (0.91-1.28)	0.03	59%		1.05 (0.73-1.51)	0.01	66%		1.11 (1.04-1.20)	0.15	37%		1.13 (0.95-1.33)	0.31	28%		1.17 (0.97-1.41)	0.09	51%	
Stratified by Physical Activity																					
Advanced ⁷	Low	1.12 (1.00-1.26)	0.01	63%	0.13	1.10 (0.97-1.24)	0.22	27%	0.34	1.04 (1.00-1.09)	0.29	17%	0.39	1.10 (0.99-1.23)	0.38	6%	<0.01	1.12 (1.00-1.26)	0.03	60%	<0.01
	Med	1.00 (0.92-1.08)	0.41	3%		0.92 (0.73-1.17)	<0.01	72%		1.03 (0.98-1.08)	0.19	31%		0.88 (0.74-1.04)	<0.01	84%		0.93 (0.83-1.03)	0.21	31%	
	High	1.06 (0.97-1.16)	0.77	0%		0.99 (0.81-1.21)	0.03	56%		1.08 (1.02-1.13)	0.22	26%		1.23 (1.02-1.49)	0.09	49%		1.13 (0.98-1.30)	0.06	55%	
Advanced restricted ⁸	Low	1.04 (0.94-1.15)	0.22	26%	0.85	1.08 (0.93-1.24)	0.33	13%	0.44	1.05 (1.00-1.10)	0.42	1%	0.28	1.08 (0.94-1.24)	0.96	0%	0.37	1.05 (0.95-1.16)	0.65	0%	0.37
	Med	1.04 (0.91-1.19)	0.11	42%		0.91 (0.71-1.16)	0.03	58%		1.02 (0.97-1.07)	0.49	0%		0.90 (0.74-1.08)	0.08	74%		0.94 (0.80-1.11)	0.08	54%	
	High	0.99 (0.89-1.11)	0.91	0%		0.93 (0.67-1.27)	<0.01	75%		1.09 (1.00-1.19)	0.03	57%		1.08 (0.87-1.36)	0.15	43%		1.02 (0.88-1.18)	0.23	30%	
Prostate Cancer Mortality ⁹	Low	1.19 (1.05-1.36)	0.01	59%	<0.05	1.12 (0.98-1.28)	0.39	6%	0.17	1.05 (1.00-1.11)	0.24	24%	0.24	1.17 (1.05-1.30)	0.47	0%	<0.01	1.20 (1.08-1.33)	0.19	34%	<0.001
	Med	0.98 (0.88-1.08)	0.55	0%		0.86 (0.62-1.20)	<0.001	80%		1.05 (0.99-1.11)	0.24	25%		0.84 (0.68-1.05)	0.00	85%		0.91 (0.83-1.00)	0.48	0%	
	High	1.12 (1.00-1.26)	0.46	0%		1.03 (0.88-1.22)	0.39	5%		1.11 (1.05-1.17)	0.79	0%		1.20 (0.98-1.47)	0.23	29%		1.16 (0.97-1.39)	0.06	55%	
Removing Non-Diabetics																					
Advanced ⁷		1.05 (1.00-1.11)	0.20	26%		1.05 (0.92-1.21)	<0.01	74%		1.05 (1.03-1.08)	0.39	6%		1.03 (0.98-1.07)	0.55	0%		1.04 (0.98-1.10)	0.20	33%	
	Advanced restricted ⁸	1.01 (0.93-1.08)	0.14	36%		1.00 (0.87-1.15)	0.02	59%		1.04 (1.02-1.08)	0.62	0%		1.01 (0.94-1.07)	0.67	0%		0.98 (0.92-1.05)	0.56	0%	
Prostate Cancer Mortality ⁹		1.08 (1.02-1.15)	0.33	12%		1.05 (0.90-1.22)	<0.01	66%		1.07 (1.04-1.11)	0.25	21%		1.04 (0.99-1.09)	0.65	0%		1.05 (1.00-1.10)	0.44	0%	

¹Multivariable relative risks (MVRs) were adjusted for race (Caucasian, African-American, Asian, Hispanic, other), education (<high school, high school, >high school), marital status (married, never married, widowed, divorced), alcohol (0, >0<5, 5-15, 15-30 and ≥30g/day), smoking habits (never, past smoker and <15 pack years, past smoker and 15+ pack years, current smoker and <40 pack years, and current smoker and pack years ≥40), height (<1.70, 1.70-1.75, 1.75-1.80, 1.80-1.85, ≥1.85m), except for JPHC1 and JPHC2 in which the .05m category increments ranged from <1.60 to >1.75m, BMI (<23, 23-25, 25-30, >30kg/m²), (physical activity (low, medium, high), prostate cancer family history (no, yes), personal history of diabetes (no, yes) multiple vitamin use (no, yes), and dietary calcium (quintiles), dietary lycopene (quintiles), and total energy intake (kcal/d, continuous); for adjustment, these variables were entered directly into the multivariable model or, for studies with less than 200 cases, these variables were modeled using the propensity scores.

²Continuous estimate was based on an increment of 5kg/m² for BMI and BMI at younger ages, 10cm for waist circumference, 5cm for hip circumference and 0.05 for waist to hip ratio.

³For this multivariable model, we did not adjust for BMI at baseline

⁴p-value, test for between-studies heterogeneity

⁵I² value is based on the highest category

⁶p-value, test for interaction

⁷"Advanced": defined as cancers with extension to or fixation to adjacent structures other than seminal vesicles, i.e. T4, N1, M1 or fatal;

⁸"Advanced (restricted)": same as "advanced" but excluding localized cases and cases with missing stage, who died of prostate cancer during follow-up;

⁹"Prostate Cancer Mortality": defined when prostate cancer was the underlying cause of death

Supplemental table 3. Funding of individual cohorts

Study Name (Acronym)	Country	Funding Source
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC)	Finland	The ATBC Study is supported in part by the Intramural Research Program of the NIH and the National Cancer Institute, and by U.S. Public Health Service contract HHSN261201500005C from the National Cancer Institute, Department of Health and Human Services.
Beta-Carotene and Retinol Efficacy Trial (CARET)	USA	The CARET study is supported by U01 CA 063673, R01 CA 096789, UM1 CA 167462.
CLUE II: Campaign Against Cancer and Heart Disease (CLUE II)	USA	Funding for the CLUE II cohort was provided by grants from the National Cancer Institute (U01-CA-086308) and the National Institute on Aging (U01-AG-18033). Cancer incidence data were provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Maryland Department of Health, 201 W. Preston Street, Room 400, Baltimore, MD 21201. We acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that support the collection and availability of the cancer registry data.
Cancer Prevention Study-II Nutrition Cohort (CPS II)	USA	The American Cancer Society funds the creation, maintenance, and updating of the CPS-II study.
Cohort of Swedish Men (COSM)	Sweden	The COSM study was supported by grants from the Swedish Research Council and the Swedish Cancer Foundation.

European Prospective Investigation into Cancer and Nutrition (EPIC)	10 European countries	The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) PI13/00061 (EPIC-Granada) and, PI13/01162 (EPIC-Murcia), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII Health Research Funds RD12/0036/0018 (cofounded by FEDER funds/European Regional Development Fund ERDF) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK).
Health Professionals Follow-Up Study (HPFS)	USA	The HPFS was supported by grants from the National Institute of Health, National Cancer Institute: UM1 CA167552.

The Japan Public Health Center-Based Study Cohort 1 (JPHC I) and Cohort 2 (JPHC II)	Japan	The JPHC studies were supported by grants from the National Cancer Center Research and Development Fund (23-A-31 and 26-A-2) (since 2011) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (from 1989 to 2010).
Melbourne Collaborative Cohort Study (MCCS)	Australia	The MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria.
Multiethnic Cohort (MEC)	USA	The MEC study was supported by a grant from the National Institutes of Health, National Cancer Institute: R37 CA54281 and U01 CA164973 .
The Netherlands Cohort Study (NLCS)	Netherlands	The NLCS was supported by grants from the Dutch Cancer Society.
The NIH-AARP Diet and Health Study (NIH-AARP)	USA	AARP research was supported (in part) by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.
Prostate Cancer Prevention Trial (PCPT)	USA	Funding for the Prostate Cancer Prevention Trial was provided by the National Cancer Institute of the National Institutes of Health grant award numbers 1UG1CA189974 and 5UM1CA182883-
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)	USA	This research was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute.